A RANDOMIZED, MULTICENTRE PHASE IIa OPEN-LABEL, ACTIVE-COMPARATOR TRIAL TO ASSESS THE EFFICACY AND SAFETY OF TWO REGIMENS OF BUCILLAMINE 100 MG TABLETS AS COMPARED TO COLCHICINE 0.6 MG TABLETS FOR THE TREATMENT OF AN ACUTE GOUT FLARE IN SUBJECTS WITH MODERATE TO SEVERE GOUT

Trial Profile

A RANDOMIZED, MULTICENTRE PHASE IIa OPEN-LABEL, ACTIVE-COMPARATOR TRIAL TO ASSESS THE EFFICACY AND SAFETY OF TWO REGIMENS OF BUCILLAMINE 100 MG TABLETS AS COMPARED TO COLCHICINE 0.6 MG TABLETS FOR THE TREATMENT OF AN ACUTE GOUT FLARE IN SUBJECTS WITH MODERATE TO SEVERE GOUT

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2016

At a glance

  • Drugs Bucillamine (Primary) ; Colchicine
  • Indications Gout
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Revive Therapeutics
  • Most Recent Events

    • 01 Dec 2015 Status changed from active, no longer recruiting to completed, based on the information provided in a Revive Therapeutics media release.
    • 01 Dec 2015 Results published in the Revive Therapeutics Media Release
    • 29 Oct 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top